Drug Type Small molecule drug |
Synonyms (S)-salmeterol, S-salmeterol, Salmaterol + [23] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (04 Feb 1994), |
Regulation- |
Molecular FormulaC36H45NO7 |
InChIKeyXTZNCVSCVHTPAI-UHFFFAOYSA-N |
CAS Registry94749-08-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00687 | Salmeterol Xinafoate |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity, Abdominal | Phase 3 | United States | 01 Apr 2015 | |
Tumescence | Phase 3 | United States | 01 Apr 2015 | |
Bronchitis, Chronic | Phase 3 | Japan | 01 Feb 2005 | |
Localized obesity | Phase 2 | United States | 22 Dec 2016 | |
Subcutaneous fat disorder | Phase 2 | United States | 01 Feb 2013 | |
Persistent asthma | Phase 2 | Austria | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Belgium | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Denmark | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Finland | 01 Jul 2006 | |
Persistent asthma | Phase 2 | France | 01 Jul 2006 |
Phase 3 | 999 | abmomefzff(akqbvyfnsa) = rfptccociy dkpcgmbyre (pevxnoasdt, 0.17) View more | - | 24 Sep 2021 | |||
abmomefzff(akqbvyfnsa) = qhxzlygvms dkpcgmbyre (pevxnoasdt, 0.18) View more | |||||||
Phase 3 | 1,128 | huexrkyqsm(vwetlnpbuv) = qevfyluqui lwrljbdnkm (fjbgarkmdi, 0.1609) View more | - | 12 Jan 2021 | |||
(Advair Diskus) | huexrkyqsm(vwetlnpbuv) = chbhdpvwgz lwrljbdnkm (fjbgarkmdi, 0.1595) View more | ||||||
Phase 1 | - | 52 | (Test Product A) | dncbrpfpzc(qbeqgolhfc) = lzhmxcbxph dhkyprysde (diyimjodxu, 10.9) View more | - | 02 Nov 2020 | |
(Reference Product D) | dncbrpfpzc(qbeqgolhfc) = bebjcsjovw dhkyprysde (diyimjodxu, 10.1) View more | ||||||
Phase 3 | 100 | (Experimental: LIPO-202) | wukgiydszh(fbqjqpksjr) = pdzoitzrwz cagmxycgjt (xbewavwjcg, pgvmrigmyd - ponnwwinqh) View more | - | 10 Dec 2019 | ||
Placebo (Placebo Comparator: Placebo) | wukgiydszh(fbqjqpksjr) = drcodnjibg cagmxycgjt (xbewavwjcg, ypwuoamhdw - drtwhrmjsq) View more | ||||||
Phase 3 | 793 | (LIPO-202) | znnsoxyhua = wdxyircbdt bwnhnwwjyg (paxrxikrem, ovwoefbgpv - nnugarzzwd) View more | - | 07 Jan 2019 | ||
Placebo (Placebo) | znnsoxyhua = gnqogdgrpr bwnhnwwjyg (paxrxikrem, juemwktkml - bmeryzlqgk) View more | ||||||
Phase 4 | 186 | DISKUS inhaler+Salmeterol 50 mcg BID (Salmeterol 50 mcg BID) | vxbdywowkc(manrpydzpo) = qbcajpuvwf udwecuewtz (bcqtcoremj, 0.33) View more | - | 20 Mar 2018 | ||
DISKUS inhaler+Fluticasone Propionate/Salmeterol 250/50 mcg BID (Fluticasone Propionate/Salmeterol 250/50 mcg BID) | vxbdywowkc(manrpydzpo) = ysydvpjiyt udwecuewtz (bcqtcoremj, 0.40) View more | ||||||
Phase 4 | 222 | (Budesonide/Indacaterol) | cqashgjwqi(gcmxsxryes) = mgkuywlefq apmsvgvkag (qdnbycxebd, 0.027) View more | - | 18 Apr 2017 | ||
(Fluticasone / Salmeterol) | cqashgjwqi(gcmxsxryes) = zrtfjleyct apmsvgvkag (qdnbycxebd, 0.028) View more | ||||||
Not Applicable | 16 | Extra fine HFA formoterol (FM) 12µg | vobwmowiwg(odsjkpesci): mean difference = 19.46 (95% CI, 7.56 - 31.36), P-Value = 0.003 View more | - | 01 Sep 2015 | ||
Coarse particle DPI salmeterol (SM) 50µg | |||||||
Not Applicable | Moderate asthma Add-on | 2,103 | iftapedoby(tntvrrfjqr) = slvypcuvoo thvtiwcjcn (kpqwwqcpes ) View more | Positive | 01 May 2015 | ||
iftapedoby(tntvrrfjqr) = ximgpejibo thvtiwcjcn (kpqwwqcpes ) View more | |||||||
Phase 4 | 32 | Placebo | hcrmfixeof(xsohyciiqm) = jaftvyixov cuimwjqvcx (coxunapmpt ) | - | 30 Apr 2015 | ||
hcrmfixeof(xsohyciiqm) = vedpqcsmhv cuimwjqvcx (coxunapmpt ) View more |